Eli Lilly launches first and only RET inhibitor for patients with metastatic solid tumours in India

image credit- freepik

Eli Lilly and Company India has  announced the launch of Tanstrive^® (selpercatinib) in India, following marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) for patients with locally advanced or metastatic solid tumours with a rearranged during transfection (RET) gene.

Tanstrive^® (selpercatinib) is designed to selectively target RET alterations and block the abnormal signalling pathways that drive tumour growth.

As an oral therapy administered twice daily, Tanstrive^® (selpercatinib) offers a targeted treatment approach for eligible patients whose cancers are driven by RET alterations.

By targeting the underlying molecular drivers of disease, Tanstrive^® (selpercatinib) supports precision treatment based on biomarker identification and has demonstrated rapid and durable responses, including meaningful activity in patients with central nervous system (CNS) involvement.

Tanstrive^® (selpercatinib) is a prescription medicine used to treat certain cancers caused by abnormal RET genes in:

• Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion.
• Adult and paediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC)with a RET mutation, who require systemic therapy. 
• Adult and paediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). 
• Adult and paediatric patients 2 years of age and older with locally advanced or metastatic solid tumours with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.